|
June 1, 2023
|
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
|
|
|
April 11, 2023
|
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
|
|
|
March 18, 2023
|
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
|
|
|
March 17, 2023
|
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
|
|
|
March 6, 2023
|
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
|
|
|
February 9, 2023
|
Connect Biopharma Reports CBP-201 Global Phase 2 Asthma Trial Achieves Full Enrollment
|
|
|
February 6, 2023
|
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
|
|
